The Menkes Disease Market is Trending by Growing Awareness of Rare Diseases

Menkes disease is an X-linked recessive disorder of copper transport which leads to impaired development of connective tissues. It is caused due to a mutation in the ATP7A gene which encodes a copper-transporting P-type ATPase essential for delivering copper to developing tissues. This results in copper deficiency in various organs and tissues. The currently available treatment options for Menkes disease include copper histidine injections and gene therapy. These treatments aim to improve copper distribution and reduce symptom severity.

The Global Menkes Disease Market is estimated to be valued at USD 165.1 million in 2024 and is expected to reach USD 259.2 million by 2031, growing at a compound annual growth rate (CAGR) of 6.65% from 2024 to 2031.

Key Takeaways

Key players: Key players operating in the Menkes Disease market are Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Orient EuroPharma Co. Ltd.

Growing demand: Rising awareness about rare diseases globally is leading to an increase in newborn screening programs for early diagnosis of Menkes disease. This is fueling the demand for treatment drugs in the Menkes Disease Market.

Global expansion: Major market players are focusing on expanding their geographic presence in emerging markets of Asia Pacific and Latin America. This is attributed to growing healthcare expenditure and increasing investment in rare disease drug development in these regions.

Market key trends

One of the major trends in the Menkes Disease market is the growing pipeline of candidate drugs and therapies. Currently, several pharmaceutical companies are conducting clinical trials for improved treatment approaches like gene therapies, drugs improving intestinal copper absorption, and copper metallochaperone therapies. This significant research focus is expected to bring novel treatment alternatives and drive the market growth over the forecast period.

Porter's Analysis
Threat of new entrants: Low as it requires high R&D investments and clinical trials to develop new treatment options for this rare genetic disorder.
Bargaining power of buyers: Moderate as there are only a limited number of treatment options available for Menkes disease currently.
Bargaining power of suppliers: High due to the limited treatment landscape and urgent unmet medical need for developing new therapies.
Threat of new substitutes: Low as there are no effective treatment substitutes currently available.
Competitive rivalry: Intense among existing players to develop novel treatments and gain maximum market share.

Geographical Regions
North America currently dominates the Menkes disease market in terms of value mainly due to high diagnosis rates and availability of limited treatment landscape in the region. The United States represents the major market for Menkes disease currently.

Asia Pacific region is poised to witness the fastest growth over the forecast period owing to increasing patient pool, rising healthcare spending, and growing awareness about rare genetic disorders in the region. Rising medical tourism across India and China for availing advanced treatment care also contributes to market growth in Asia Pacific.

Get This Report in Japanese Language: 保健大臣 疾病市場

Get This Report in Korean Language: 보건부 장관 질병 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)